![Antoni Villaró Martín](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Antoni Villaró Martín
Corporate Officer/Principal chez Ferrer Internacional SA
Profil
Antoni Villaró Martín is currently the Vice President-Corporate Strategy at Ferrer Internacional SA. Previously, he held the position of Managing Director at Otsuka Pharmaceutical Europe Ltd.
and Director at Genmedica Therapeutics SL.
Postes actifs de Antoni Villaró Martín
Sociétés | Poste | Début |
---|---|---|
Ferrer Internacional SA
![]() Ferrer Internacional SA Pharmaceuticals: MajorHealth Technology Ferrer Internacional SA engages in the development, manufacture and commercialization of pharmaceutical products for the diagnosis and treatment of cardiovascular, dermatological, gastrointestinal and respiratory conditions. It also designs and produces active ingredients and nutraceuticals for the food, cosmetics and animal feed industries. The company was founded on April 17, 1940 and is headquartered in Barcelona, Spain. | Corporate Officer/Principal | - |
Anciens postes connus de Antoni Villaró Martín
Sociétés | Poste | Fin |
---|---|---|
Genmedica Therapeutics SL
![]() Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | - |
Otsuka Pharmaceutical Europe Ltd.
![]() Otsuka Pharmaceutical Europe Ltd. Medical DistributorsDistribution Services Otsuka Pharmaceutical Europe Ltd. markets drugs, nutraceuticals and other health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. Some of the company's nutraceutical products include Pocari Sweat-electrolyte replacement beverages, Calorie Mate-energy beverages and the Calcium. Otsuka also makes products for infants under the Bean Stalk name. Additionally, the company conducts pharmaceutical research focusing on gastroenterology, oncology, dermatology, ophthalmology and the cardiovascular system. The company was founded in 1998 and is headquartered in Uxbridge, UK | Directeur Général | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Otsuka Pharmaceutical Europe Ltd.
![]() Otsuka Pharmaceutical Europe Ltd. Medical DistributorsDistribution Services Otsuka Pharmaceutical Europe Ltd. markets drugs, nutraceuticals and other health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. Some of the company's nutraceutical products include Pocari Sweat-electrolyte replacement beverages, Calorie Mate-energy beverages and the Calcium. Otsuka also makes products for infants under the Bean Stalk name. Additionally, the company conducts pharmaceutical research focusing on gastroenterology, oncology, dermatology, ophthalmology and the cardiovascular system. The company was founded in 1998 and is headquartered in Uxbridge, UK | Distribution Services |
Ferrer Internacional SA
![]() Ferrer Internacional SA Pharmaceuticals: MajorHealth Technology Ferrer Internacional SA engages in the development, manufacture and commercialization of pharmaceutical products for the diagnosis and treatment of cardiovascular, dermatological, gastrointestinal and respiratory conditions. It also designs and produces active ingredients and nutraceuticals for the food, cosmetics and animal feed industries. The company was founded on April 17, 1940 and is headquartered in Barcelona, Spain. | Health Technology |
Genmedica Therapeutics SL
![]() Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Health Technology |